



	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEE
TOTAL	11	-	20	=	0	\$18	\$0.00
INDEPENDENT	1	-	3	=	0	\$84	\$0.00
<input type="checkbox"/> FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						\$280	\$0.00
						TOTAL	\$0.00


Appl. No. 09/214,723

- ☐ Petition for ( ) month(s) extension of time pursuant to 37 C.F.R. §§ 1.17 and 1.136(a). \$0.00 for the extension of time.
- ☒ No fee is required.
- ☐ Check(s) in the amount of \$0.00 is(are) enclosed.
- ☐ Please charge Deposit Account No. 02-2448 in the amount of \$0.00. This form is submitted in triplicate.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP


By  #28,977  
for Gerald M. Murphy, Jr., #28,977

*KLR*  
GMM/KLR:gml  
0171-0613P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

ATTACHMENT

(Rev. 09/27/01)



RECEIVED

FEB 08 2002

TECH CENTER 1600/2900

PATENT  
0171-0613P

# 306  
5/13/02  
Jian

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: OKA, Takanori Conf.: 8292  
Appl. No.: 09/214,723 Group: 1655  
Filed: January 11, 1999 Examiner: SISSON, Bradley  
For: NUCLEIC ACID ASSAY PROCESS AND ASSAY  
KIT

REPLY UNDER 37 C.F.R. § 1.111

Assistant Commissioner for Patents  
Washington, DC 20231

February 6, 2002

Sir:

In reply to the Examiner's Advisory Action dated November 6, 2001, the following amendments and remarks are respectfully submitted in connection with the above-identified application.

IN THE CLAIMS:

Please amend the claims as follows:

*Sub Hq*  
~~Claim 13. (Twice Amended)~~ A nucleic acid assay process for identifying and/or quantifying a mutation or polymorphism in a double stranded sample DNA prepared by amplification of a particular region of an analyte nucleic acid which is present in a specimen, comprising the steps of:

*Q*  
providing labeled standard DNA having a nucleotide sequence the same as a mutated or polymorphic target DNA of interest,